(12) **Translation of European patent specification**

(11) **NO/EP 4214240 B1**

NORWAY

(19) NO

(51) Int Cl.

C07K 16/28 (2006.01)

A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.12.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.10.09
(86)	European Application Nr.	22754752.8
(86)	European Filing Date	2022.07.27
(87)	The European Application's Publication Date	2023.07.26
(30)	Priority	2021.07.27, US, 202163226118 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	KH ; MA ; MD ; TN
(73)	Proprietor	AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL 60064, USA
(72)	Inventor	MCCLUSKEY, Andrew, J., Chicago, IL 60064, USA SCHMIDT PAUSTIAN, Amanda, M., Chicago, IL 60064, USA SEAGAL, Jane, Chicago, IL 60064, USA WILSBACHER, Julie, L., Chicago, IL 60064, USA
(74)	Agent or Attorney	Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, 92665 ASNIÈRES-SUR-SEINE CEDEX, Frankrike

(54) Title **ANTI-CCR8 ANTIBODIES**

(56) References Cited:

WO-A1-2021/142002, WO-A1-2020/138489, EP-A1- 3 431 105

LINE BARINGTON: "Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule Binding", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 31, 19 May 2016 (2016-05-19), US, pages 16208 - 16220, XP093167668, ISSN: 0021-9258, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965569/pdf/zbc16208.pdf> DOI: 10.1074/jbc.M115.706747, GUTIERREZ JULIO ET AL: "Analysis of post-translational CCR8 modifications and their influence on receptor activity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 15, 1 April 2004 (2004-04-01), pages 14726 - 14733, XP002459212, ISSN: 0021-9258, DOI: 10.1074/JBC.M309689200

DIETMAR REUSCH ET AL: "Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 1: Separation-based methods", MABS, vol. 7, no. 1, 2 January 2015 (2015-01-02), US, pages 167 - 179, XP055694176, ISSN: 1942-0862, DOI: 10.4161/19420862.2014.986000

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

PATENTKRAV

1. Anti-CCR8-antistoff som omfatter (i) en VH-kjede omfattende tre CDR-er; og (ii) en VL-kjede omfattende tre CDR-er, hvori:

VH CDR#1 er GFIFSNAVMY (SEQ ID NO: 1);

VH CDR#2 er RIKTKFNNYATYYADAVKG (SEQ ID NO:2);

VH CDR#3 er GDRNKPFAY (SEQ ID NO:3);

VL CDR#1 er RASTSVITLLH (SEQ ID NO:4);

VL CDR#2 er GASNLES (SEQ ID NO:5); og

VL CDR#3 er QQSWNDPYT (SEQ ID NO:6);

hvori antistoffet omfatter en IgGl Fc-konstant region som er afukosylert.

2. Anti-CCR8-antistoffet ifølge krav 1, hvori antistoffet omfatter en variabel tungkjederegion omfattende aminosyresekvensen angitt som SEQ ID NO: 7 og en variabel lettkjederegion omfattende aminosyresekvensen angitt som SEQ ID NO: 8.

3. Anti-CCR8-antistoffet ifølge krav 1, hvori antistoffet omfatter en tungkjede omfattende aminosyresekvensen angitt som SEQ ID NO: 9 og en lettkjede omfattende aminosyresekvensen angitt som SEQ ID NO: 10.

4. Sammensetning omfattende et mangfold av anti-CCR8-antistoffer ifølge krav 1, hvori mer enn 80 % av anti-CCR8-antistoffene i sammensetningen er afukosylert.